natgillin/translations-raw huggingface dataset:
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) EASOTIC EPAR summary for the public 
EMEA/V/C/140 EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) EASOTIC Povzetek EPAR za javnost
Easotic has been studied in dogs in both laboratory and field trials. 
Zdravilo Easotic je bilo preučeno na psih v laboratoriju in v preskušanjih na terenu.
The use of ear preparations may be associated with damage to hearing. 
Uporaba pripravkov za ušesa je lahko povezana z okvaro sluha.
This stops the bacteria growing, resulting in their death. 
To prepreči rast bakterij in povzroči, da odmrejo.
If accidental skin or eye contact occurs, wash immediately with lots of water. 
Če pride do nenamernega stika s kožo ali očmi, nemudoma izperite z obilico vode.
Gentamicin sulphate is an antibiotic that belongs to the group aminoglycosides. 
Gentamicinijev sulfat je antibiotik, ki spada v skupino aminoglikozidov.
Miconazole nitrate is an antifungal that works by preventing the formation of ergosterol, which is an important part of fungal cell walls. 
Mikonazolijev nitrat je protiglivično sredstvo, ki deluje tako, da preprečuje nastajanje ergosterola, ki je pomemben del glivičnih celičnih sten.
Two of the active substances in Easotic, miconazole nitrate and gentamicin sulphate, work against the cause of the infection, while the third one, hydrocortisone aceponate, works on the inflammation. 
Dve zdravilni učinkovini v zdravilu Easotic, mikonazolijev nitrat in gentamicinijev sulfat, delujeta proti vzroku okužbe, medtem ko tretja, hidrokortizon aceponat, deluje proti vnetju.
Easotic contains three active substances: hydrocortisone aceponate, miconazole nitrate and gentamicin sulphate. 
Zdravilo Easotic vsebuje tri zdravilne učinkovine: hidrokortizon aceponat, mikonazololijev nitrat in gentamicinijev sulfat.
Easotic is used to treat dogs that suffer from acute or recurrent episodes of ear infections (otitis externa). 
Zdravilo Easotic se uporablja za zdravljenje psov, ki trpijo zaradi akutnih ali ponavljajočih epizod vnetja ušesa (otitis externa).
Hydrocortisone aceponate is a glucocorticosteroid, which is a type of substance that helps to reduce inflammation and itching. 
Hidrokortizon aceponat je glukokortikosteroid, vrsta snovi, ki pomaga zmanjšati vnetje in srbenje.
Easotic must not be used in dogs that may be allergic to the active substances or any of the other ingredients, if the eardrum is perforated, at the same time as other medicines that can harm the ear, or in dogs with a parasite infection called generalised demodecosis (mange). 
Zdravilo Easotic se ne sme uporabljati pri psih, ki utegnejo biti alergični na zdravilne učinkovine ali katero koli drugo sestavino zdravila, če je ušesni bobnič predrt, sočasno z drugimi zdravili, ki lahko poškodujejo uho, ali pri psih s parazitsko okužbo, imenovano generalizirana demodikoza (garje).
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Easotic exceed the risks for the treatment of acute otitis externa, and acute exacerbation of recurrent otitis externa associated with bacteria susceptible to gentamicin and fungi susceptible to miconazole in particular Malassezia pachydermatis, and recommended that Easotic be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Easotic pri zdravljenju akutnega vnetja ušes in akutnih izbruhov ponavljajočega vnetja ušes, povezanih z bakterijami, občutljivimi na gentamicin, in glivicami, občutljivimi na mikonazol, zlasti Malassezia pachydermatisin, večje od z njim povezanih tveganj, ter priporočil, da se za zdravilo Easotic odobri dovoljenje za promet.
In the study, the effectiveness of Easotic was compared with that of ear drops containing three similar active substances in dogs with acute or recurrent bacterial or fungal ear infections. 
V študiji so učinkovitost zdravila Easotic primerjali z učinkovitostjo kapljic za uho, ki vsebujejo tri podobne zdravilne učinkovine, pri psih z akutnimi ali ponavljajočimi se bakterijskimi ali glivičnimi vnetji ušes.
When used at the recommended dose for five days, Easotic was as effective as the comparator medicine in improving the symptoms of ear infection (redness, swelling, ear discharge and discomfort). 
Zdravilo Easotic je bilo v priporočenem odmerku in po petdnevnem zdravljenju enako učinkovito kot primerjalno zdravilo pri izboljševanju simptomov (pordelost, otekanje, izcedek iz ušesa, nelagodnost) vnetij ušesa.
Why has Easotic been approved? 
Zakaj je bilo zdravilo Easotic odobreno?
For a full list of all side-effects reported with Easotic, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Easotic, glejte navodilo za uporabo.
What is Easotic used for? 
Za kaj se zdravilo Easotic uporablja?
It is an ear drop suspension for dogs, that is white in colour. 
Zdravilo so kapljice za uho v obliki suspenzije bele barve za pse.
If a person accidentally takes the medicine or eye irritation occurs, seek medical advice immediately and show the package leaflet or the label to a doctor. 
Če pride do nenamernega zaužitja zdravila pri človeku, se nemudoma posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali ovojnino.
How has Easotic been studied? 
Kako je bilo zdravilo Easotic raziskano?
How does Easotic work? 
Kako zdravilo Easotic deluje?
They often lead to the ear(s) being inflamed (red, swollen and itchy). 
Vnetja ušes pri psih lahko povzročijo bakterije ali glivice, zaradi česar se uho(ušesa) vname(jo) (postanejo rdeča, zatečena in srbeča).
What is Easotic? 
Kaj je zdravilo Easotic?
List of the name, pharmaceutical form, strength of the medicinal product, route of administration, marketing authorisation holder in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila in imetnikov dovoljenj za promet z zdravilom v državah članicah
Austria implant, pre-filled syringe subcutaneous use 
Avstrija implantat, napolnjena injekcijska brizga
Further information on NexGard can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/NexGard. 
Nadaljnje informacije o zdravilu NexGard so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/NexGard.
The European Medicines Agency decided that NexGard's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila NexGard večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
NexGard received a marketing authorisation valid throughout the EU on 11 February 2014. 
Zdravilo NexGard je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 11. februarja 2014.
People handling the medicine should wash their hands after handling the product. 
Osebe, ki rokujejo z zdravilom, si morajo po rokovanju z zdravilom umiti roke.
The effectiveness of NexGard was investigated in both laboratory and field studies. 
Učinkovitost zdravila Nexgard so proučevali v laboratorijskih in terenskih študijah.
Because parasites must start feeding on the dog in order to be killed by the medicine, there may be a risk of transmission of diseases with which they may be infected. 
Ker se morajo bolhe in klopi začeti hraniti s krvjo psa, da bi jih zdravilo lahko uničilo, obstaja tveganje za prenos bolezni, s katerimi so ti zajedavci lahko okuženi.
It blocks the normal movement of charged chloride particles (ions) in and out of nerve cells, especially those associated with gamma-aminobutyric acid (GABA), a substance which conveys messages between nerves (neurotransmitter). 
Zavira normalno prehajanje nabitih kloridnih delcev (ionov) v živčne celice in iz njih, in sicer zlasti tistih, ki so povezani z gamaaminomasleno kislino (GABA), tj. snovjo, ki prenaša sporočila med živci (živčna prenašalca).
Afoxolaner kills parasites by causing an over-stimulation of their nervous system. 
Afoksolaner zajedavce ubije tako, da v pretirano stimulira njihov živčni sistem.
Why is NexGard authorised in the EU? 
Zakaj je zdravilo NexGard odobreno v EU?
In order for the active substance to have an effect, fleas and ticks must attach to the skin and commence feeding on the dog's blood. 
Da bi bili bolhe in klopi izpostavljeni učinkovini, se morajo pritrditi na kožo in se začeti hraniti s krvjo psa.
NexGard kills fleas within 8 hours and ticks within 48 hours. 
Zdravilo NexGard bolhe ubije v osmih urah, klope pa v 48 urah.
For more information about using NexGard, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila NexGard glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
It may be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites). 
Uporablja se lahko kot del zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijska reakcija na ugrize bolh).
Other information about NexGard 
Druge informacije o zdravilu NexGard:
An overview of NexGard and why it is authorised in the EU 
Pregled zdravila NexGard in zakaj je odobreno v EU
NexGard reduced the number of fleas and ticks by at least 98% and was at least as effective as a spoton medicine containing pyriprole (another medicine against fleas and ticks). 
Zdravilo NexGard je zmanjšalo število bolh in klopov za vsaj 98 % in je bilo vsaj tako učinkovito kot zdravilo za kožni nanos, ki vsebuje piriprol (drugo zdravilo proti bolham in klopom).
NexGard reduced the number of live mites by 97% 56 days after starting treatment and by 98% 84 days after starting treatment. 
Zdravilo Nexgard je število živih garjavcev zmanjšalo za 97 % 56 dni po začetku zdravljenja in za 98 % 84 dni po začetku zdravljenja.
NexGard reduced the number of live mites by 96% 28 days after starting treatment and by 100% 56 days after starting treatment. 
Zdravilo NexGard je število živih garjavcev zmanjšalo za 96 % 28 dni po začetku zdravljenja in za 100 % 56 dni po začetku zdravljenja.
Treatment should be repeated at monthly intervals during the flea or tick seasons, monthly for demodectic mange until the mange is successfully treated (as confirmed by two negative skin scrapings one month apart) and monthly for two months for sarcoptic mange, or longer if treatment is unsuccessful as indicated by clinical signs and skin scrapings. 
Zdravilo je treba dajati v mesečnih razmikih v obdobjih leta, ko so bolhe ali klopi prisotni, in v vsak mesec pri garjavici vrste Demodex canis, dokler ni uspešno pozdravljena (in potrjena z negativnimi rezultati dveh kožnih brisov, vzetih v enomesečnem razmiku), ter vsak mesec dva meseca zapored pri garjavici vrste Sarcoptes scabiei oziroma dlje, če klinični znaki in brisi kože nakazujejo, da zdravljenje ni bilo uspešno.
What is NexGard and what is it used for? 
Kaj je zdravilo NexGard in za kaj se uporablja?
What are the risks associated with NexGard? 
Kakšna tveganja so povezana z zdravilom NexGard?
What benefits of NexGard have been shown in studies? 
Kakšne koristi je zdravilo NexGard izkazalo v študijah?
In an EU field study involving 146 dogs with flea and/or tick infestations, a single treatment with NexGard was effective in treating flea and tick infestations in dogs for up to 30 days after treatment. 
V terenski študiji, ki so jo opravili v EU in v katero so vključili 146 psov z bolhami in/ali klopi, je bila ena sama uporaba zdravila NexGard učinkovita proti bolham in klopom pri psih v obdobju do 30 dni po zdravljenju.
After being given, its actions last for at least 5 weeks against fleas and up to one month against ticks. 
Po uporabi zdravilo proti bolham deluje najmanj pet tednov, proti klopom pa od enega meseca.
The active substance in NexGard, afoxolaner, acts as an ‘ectoparasiticide'. 
Učinkovina v zdravilu NexGard, afoksolaner, deluje kot ektoparaziticid.
This results in uncontrolled activity of the nervous system and the paralysis and 
tem povzroči nenadzorovano delovanje živčnega sistema ter paralizo in smrt bolh, klopov in garjavcev.
NexGard is a medicine used to treat infestations with fleas and ticks, as well as demodectic and sarcoptic mange (skin infestations caused by two different types of mites) in dogs. 
NexGard je zdravilo, ki je namenjeno zdravljenju infestacij z bolhami in klopi ter garjavice vrste Demodex canis in Sarcoptes scabiei (kožne garjavosti, ki jo povzročata dve vrsti garjavcev) pri psih.
NexGard is available as chewable tablets in four different strengths for use in dogs of different weights. 
Zdravilo NexGard je na voljo v obliki žvečljivih tablet štirih različnih jakosti, namenjenih za uporabo pri psih z različno telesno maso.
A second EU field study involved 31 dogs with demodectic mange which were treated monthly on 3 occasions with NexGard. 
V drugo terensko študijo, opravljeno v EU, so vključili 31 psov z garjavico vrste Demodex canis, ki so jih trikrat zapored mesečno zdravili z zdravilom NexGard.
NexGard contains the active substance afoxolaner. 
Zdravilo NexGard vsebuje učinkovino afoksolaner.
How does NexGard work? 
Kako zdravilo NexGard deluje?
A third EU field study involved 38 dogs with sarcoptic mange which were treated monthly for two months with NexGard. 
V tretjo terensko študijo so vključili 38 psov z garjavico vrste Sarcoptes scabiei, ki so zdravilo NexGard prejeli enkrat na mesec dva meseca zapored.
How is NexGard used? 
Kako se zdravilo NexGard uporablja?
NexGard is given as a tablet of the appropriate strength for the dog's bodyweight. 
Zdravilo NexGard se daje v obliki tablet, in sicer v jakosti, ki ustreza telesni masi psa.
Only one chewable tablet at a time should be removed from the blister to prevent children from accessing the product. 
Da bi otrokom preprečili neposreden stik z zdravilom, je treba iz pretisnega omota jemati vsako žvečljivo tableto posebej.
> 3 hours to ≤ 7 days 
> 3 ure do ≤ 7 dni
Date of first authorisation: 01 September 2010 Date of latest renewal: 06 September 2015 
Datum prve odobritve: 01. september 2010 Datum zadnjega podaljšanja: 01. september 2015
These patients should be monitored closely. 
Takšne bolnike je treba skrbno nadzorovati.
A risk to the newborns/infants cannot be excluded. 
Tveganja za novorojenčka/dojenčka ni mogoče izključiti.
It will be given to you into your vein over 10 minutes. 
Dobili ga boste v veno v teku 10 minut.
This medicinal product must not be mixed with other medicinal products except those mentioned in section 4.2. 
Zdravila ne smemo mešati z drugimi zdravili, razen s tistimi, ki so omenjena v poglavju 4.2.
Variations of colour within this range do not affect potency. 
Sprememba barve v tem razponu ne vpliva na učinek.
The company will start to include the pre-infusion check list in packs packed at the packaging site as soon as possible but at the latest on 15 November 2012. 
Kontrolni seznam bo s strani podjetja vključen v pakiranja zdravila na mestu, kjer poteka pakiranje, in sicer čim prej, vendar najkasneje do 15. novembra 2012.
Efficacy versus amiodarone (AVRO) 
Učinkovitost v primerjavi z amiodaronom (AVRO):
These reactions occurred around the time of infusion, were transient and were rarely treatment limiting. 
Te reakcije so se pojavile okrog časa infundiranja, bile so prehodne in so redko omejile zdravljenje.
Detailed information on warnings and precautions relating to side effects that could occur are presented in section 4. 
Podrobne informacije o opozorilih in previdnostnih ukrepih v zvezi z neželenimi učinki, ki se lahko pojavijo, so predstavljene v poglavju 4.
If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time. 
Če predložitev PSUR in posodobitev RMP sovpadata, se lahko predložita istočasno.
By 90 minutes after the start of infusion, this difference was reduced to 8.1 msec. 
Do 90. minute po začetku infundiranja se je ta razlika zmanjšala na 8,1 ms.
Overall, BRINAVESS was effective in 70.2% (1,359/1,936) of these patients. 
V celoti gledano je bil BRINAVESS učinkovit pri 70,2% (1.359/1.936) teh bolnikov.
Does the patient have a systolic blood pressure < 100 mm Hg? 
Ali ima bolnik sistolični krvni tlak < 100 mm Hg?
If any of the above apply to you (or you are not sure), talk to your doctor. 
Če kaj od navedenega velja za vas (ali če niste prepričani), se posvetujte z zdravnikom.
Patients who did not respond to treatment were managed by the physician using standard care. 
Bolnike, ki se na zdravljenje niso odzvali, je zdravnik obravnaval v skladu s standardno oskrbo.
Patients with body weight > 113 kg: 
Bolniki s telesno maso > 113 kg:
In patients with hepatic impairment, exposures were elevated by 9 to 25 %. 
Pri bolnikih z okvaro jeter je bila izpostavljenost za 9 do 25 % večja.
Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon 
Seznam neželenih učinkov Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000
Key elements to be included in the educational material: 
Ključni elementi, ki morajo biti vključeni v izobraževalnem gradivu: 1.
With continuation of the medicine infusion as recommended above, the majority of these patients continue to convert to sinus rhythm. 
Z nadaljevanjem infundiranja zdravila, kot je priporočeno zgoraj, večina teh bolnikov preide v sinusni ritem.
5928 LC Venlo 
5928 LC Venlo Nizozemska
If you are not sure, talk to your doctor before you use this medicine. 
Če niste prepričani, se posvetujte z zdravnikom, preden uporabite to zdravilo.
Your doctor may decide to stop the infusion if he observes any of the following abnormal changes of: 
Zdravnik se lahko odloči za prenehanje infundiranja zdravila, če opazi naslednje nenormalne spremembe:
When giving BRINAVESS, follow these instructions: 
Pri dajanju zdravila upoštevajte naslednja navodila:
Vernakalant is extensively and rapidly distributed in the body, with a volume of distribution of approximately 2 l/kg. 
Vernakalant se v telesu hitro in obsežno porazdeli; volumen porazdelitve je približno 2 l/kg.
The European Medicines Agency has waived the obligation to submit the results of studies with vernakalant in all subsets of the paediatric population in atrial fibrillation (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z vernakalantom za vse podskupine pediatrične populacije za atrijsko fibrilacijo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
(≥ 1/1,000 to < 1/100). 
do < 1/100).
Information on how to prepare the solution is available at the end of this leaflet. 
Informacije o pripravi raztopine so na voljo na koncu tega navodila za uporabo.
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve PSUR za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in vseh kasnejših posodobitvah, objavljenem na evropskem spletnem portalu o zdravilih.
• if you are allergic to vernakalant hydrochloride or any of the other ingredients of this medicine (listed in section 6) 
• če ste alergični na vernakalantijev klorid ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Tell your doctor if you have a pacemaker. 
Zdravniku morate povedati, če imate srčni spodbujevalnik.
No patients with NYHA III/IV were included in the study. 
V študijo niso bili vključeni bolniki z NYHA III/IV.
Cumulative doses above 565 mg have not been evaluated. 
Kumulativni odmerki, večji od 565 mg, niso bili ovrednoteni.
In general, bradycardia responded well to discontinuation of treatment and/or administration of atropine. 
Na splošno so se bolniki, pri katerih se je pojavila bradikardija, dobro odzvali na prenehanje zdravljenja in/ali uporabo atropina.
• pain in your mouth or throat 
• bolečina v ustih ali grlu
In the remaining patients, electrical cardioversion can be recommended. 
Za preostale bolnike je mogoče priporočiti elektrokonverzijo.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you. 
Preden začnete uporabljati to zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
The diluted sterile concentrate is chemically and physically stable for 12 hours at or below 25 °C. 
Razredčeni sterilni koncentrat je kemično in fizikalno stabilen 12 ur pri temperaturi do vključno 25 °C.
The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah.
For atrial fibrillation lasting less than 48 hours, immediate cardioversion was allowed. 
Za atrijsko fibrilacijo, ki je trajala manj kot 48 ur, je bila dovoljena takojšnja kardioverzija.
To ensure proper administration, a sufficient amount of BRINAVESS 20 mg/ml should be prepared at the outset of therapy to deliver the initial and second infusion should it be warranted. 
Za zagotovitev pravilnega dajanja je treba že na začetku zdravljenja pripraviti dovolj zdravila BRINAVESS 20 mg/ml, da je mogoče dati začetno infuzijo in drugo infuzijo, če se ta izkaže za potrebno.
If these events occur during the first infusion of vernakalant, patients should not receive the second dose. 
Če se takšni dogodki pojavijo med prvo infuzijo vernakalanta, bolniki ne smejo dobiti drugega odmerka tega zdravila.
However, a syringe pump is acceptable provided that the calculated volume can be accurately given within the specified infusion time. 
Sprejemljiva pa je tudi injekcijska črpalka, če je izračunana količina lahko natančno aplicirana v določenem času za infundiranje.
Pharmacotherapeutic group: Cardiac therapy, other antiarrhythmics class I and III; ATC code: C01BG11. 
Farmakoterapevtska skupina: zdravila za bolezni srca, drugi antiaritmiki skupine I in III; oznaka ATC: C01BG11.
Do not use this medicine if you notice particulate matter or discolouration. 
Tega zdravila ne uporabite, če v njem opazite delce ali če je obarvano.
Studies in animal have shown malformations after repeated oral exposure (see section 5.3). 
Študije na živalih so po ponavljajoči se peroralni izpostavljenosti pokazale malformacije (glejte poglavje 5.3).
The Marketing Authorisation Holder shall provide a check list in each pack, the text of which is included in Annex IIIA. 
Imetnik dovoljenja za promet z zdravilom mora vsakemu pakiranju priložiti kontrolni seznam, katerega besedilo se nahaja v Dodatku IIIA.
If any of the following signs or symptoms occurs, the administration of vernakalant should be discontinued and these patients should receive appropriate medical management: 
Če se pojavi kateri koli od naslednjih znakov ali simptomov, je treba z dajanjem vernakalanta prenehati, bolniki pa morajo biti deležni ustrezne terapevtske obravnave:
Its use in these patients is not recommended. 
Zato pri bolnikih s temi boleznimi njegove uporabe ni mogoče priporočiti.
ACT III BRINAVESS Placebo P-Value† BRINAVESS Placebo P-Value† 
BRINAVESS placebo vrednost p†
The Marketing Authorisation Holder must agree about the content and format of the educational material, together with a communication plan, with the national competent authority prior to distribution. 
Imetnik dovoljenja za promet z zdravilom mora pred distribucijo doseči dogovor z nacionalnim pristojnim organom glede vsebine in oblike izobraževalnega gradiva, skupaj z načrtom komunikacije.
If your heart beat has not returned to normal 15 minutes after the end of your first dose, you may be given a second dose. 
Če se vam srčni utrip ne normalizira v 15 minutah po koncu prvega odmerka, lahko dobite drugi odmerek.
Pharmacodynamics effects 
Farmakodinamični učinki